MAOB and drug-induced dyskinesia: MAO-B inhibitors enable neurologists to delay the introduction of levodopa therapy in the early stages and to optimize the management of levodopa-related motor complications (fluctuations and dyskinesias) in more advanced stages [2, 12, 16, 23, 24].